CORCEPT THERAPEUTICS INC Earnings Per Share (Diluted)
CORCEPT THERAPEUTICS INC (CORT) reported Earnings Per Share (Diluted) of $0.36 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC earnings per share, diluted for the quarter ending 2026-06-30 was $0.36, a 24.14% increase year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for the quarter ending 2026-03-31 was -$0.30, a 276.47% decline year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for the quarter ending 2025-12-31 was $0.20, a 21.86% decline year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for the quarter ending 2025-09-30 was $0.16, a 60.98% decline year-over-year.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for fiscal 2025 was $0.82, a 33.33% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for fiscal 2024 was $1.23, a 30.85% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for fiscal 2023 was $0.94, a 8.05% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC earnings per share, diluted for fiscal 2022 was $0.87, a 2.25% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.36 10-Q · filed 2026-07-29 | $0.09 10-Q · filed 2026-07-29 | $0.30 derived: net income ÷ weighted average shares · filed 2026-07-29 | $0.47 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2026-03-31 | -$0.30 10-Q · filed 2026-04-30 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.11 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.40 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2025-12-31 | $0.20 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.36 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.65 derived: net income ÷ weighted average shares · filed 2026-07-29 | $0.82 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.16 10-Q · filed 2025-11-04 | $0.45 derived: net income ÷ weighted average shares · filed 2026-07-29 | $0.62 10-Q · filed 2025-11-04 | $0.87 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2025-06-30 | $0.29 10-Q · filed 2026-07-29 | $0.46 10-Q · filed 2026-07-29 | $0.71 derived: net income ÷ weighted average shares · filed 2026-07-29 | $1.12 derived: net income ÷ weighted average shares · filed 2026-07-29 |
| 2025-03-31 | $0.17 10-Q · filed 2026-04-30 | $0.42 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.83 derived: net income ÷ weighted average shares · filed 2026-04-30 | $1.14 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-12-31 | $0.25 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.66 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.98 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.23 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.41 10-Q · filed 2025-11-04 | $0.73 derived: net income ÷ weighted average shares · filed 2025-11-04 | $0.98 10-Q · filed 2025-11-04 | $1.26 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2024-06-30 | $0.32 10-Q · filed 2025-07-31 | $0.57 10-Q · filed 2025-07-31 | $0.85 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.13 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2024-03-31 | $0.25 10-Q · filed 2025-05-05 | $0.53 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.81 derived: net income ÷ weighted average shares · filed 2026-02-24 | $1.06 derived: net income ÷ weighted average shares · filed 2026-02-24 |
| 2023-12-31 | $0.28 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.56 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.81 derived: net income ÷ weighted average shares · filed 2026-02-24 | $0.94 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.28 10-Q · filed 2024-10-30 | $0.53 derived: net income ÷ weighted average shares · filed 2024-10-30 | $0.66 10-Q · filed 2024-10-30 | $0.80 derived: net income ÷ weighted average shares · filed 2025-02-26 |
| 2023-06-30 | $0.25 10-Q · filed 2024-07-29 | $0.38 10-Q · filed 2024-07-29 | $0.52 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.82 derived: net income ÷ weighted average shares · filed 2025-02-26 |
| 2023-03-31 | $0.14 10-Q · filed 2024-05-01 | $0.28 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.58 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.81 derived: net income ÷ weighted average shares · filed 2025-02-26 |
| 2022-12-31 | $0.14 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.44 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.68 derived: net income ÷ weighted average shares · filed 2025-02-26 | $0.87 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.30 10-Q · filed 2023-11-01 | $0.53 derived: net income ÷ weighted average shares · filed 2023-11-01 | $0.73 10-Q · filed 2023-11-01 | $1.00 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2022-06-30 | $0.24 10-Q · filed 2023-08-02 | $0.44 10-Q · filed 2023-08-02 | $0.70 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.94 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2022-03-31 | $0.20 10-Q · filed 2023-05-03 | $0.46 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.71 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.91 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2021-12-31 | $0.26 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.51 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.71 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.89 10-K · filed 2024-02-15 |
| 2021-09-30 | $0.24 10-Q · filed 2022-11-03 | $0.45 derived: net income ÷ weighted average shares · filed 2022-11-03 | $0.63 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.21 10-Q · filed 2022-08-04 | $0.39 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.18 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.20 10-K · filed 2021-02-23 | $0.85 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.17 10-Q · filed 2021-11-03 | $0.65 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $0.23 10-Q · filed 2021-07-29 | $0.48 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.25 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.24 10-K · filed 2021-02-23 | $0.77 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $0.22 10-K · filed 2021-02-23 | $0.53 10-Q · filed 2020-11-03 | ||
| 2019-06-30 | $0.17 10-K · filed 2021-02-23 | $0.31 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $0.15 10-K · filed 2021-02-23 | |||
| 2018-12-31 | $0.18 10-K · filed 2020-02-24 | $0.60 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $0.14 10-K · filed 2020-02-24 | $0.42 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $0.14 10-K · filed 2020-02-24 | $0.28 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $0.14 10-K · filed 2020-02-24 | |||
| 2017-12-31 | $0.77 10-K · filed 2019-02-26 | $1.04 10-K · filed 2020-02-24 | ||
| 2017-09-30 | $0.11 10-K · filed 2019-02-26 | $0.25 10-Q · filed 2018-11-02 | ||
| 2017-06-30 | $0.10 10-K · filed 2019-02-26 | $0.14 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $0.04 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $0.07 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $0.02 10-Q · filed 2017-11-03 | $0.03 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | $0.01 10-Q · filed 2017-08-02 | $0.01 10-Q · filed 2017-08-02 | ||
| 2015-12-31 | -$0.06 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |